Gold Standard Diagnostics Achieves Record Growth with the AIX1000™ System with its RPR Assay, a Syphilis Testing Method
With more than 13 million Rapid Plasma Reagin assay tests performed, the AIX1000 is now the industry standard in syphilis serology screening
Davis, California – (May 30, 2018) Gold Standard Diagnostics, Corp., a privately held clinical diagnostics company, today announced record growth of its AIX1000 system with its RPR Assay, a Syphilis Testing Method.
The U.S. Food and Drug Administration (FDA) cleared system automates the performance of the rapid plasma reagin (RPR) assay, used by clinical diagnostic laboratories as an aid in syphilis infection diagnosis. Widely installed and used in large reference laboratories and local public health laboratories across the U.S., the AIX1000 has been adopted as the new standard in syphilis serology screening.
“The AIX1000 is a big step forward for syphilis serology,” said Paul Doherty, Laboratory Manager at Sunrise Medical Laboratories. “The automated capabilities of the AIX1000 for performing the RPR assay and interpreting results have improved the efficiency and objectivity of syphilis testing in the clinical laboratory.”
“Finally, someone brought this test into the 21st century. It is thrilling to see an idea become a reality and solve a massive industry problem,” said John Griffiths, President of Gold Standard Diagnostics. “We are also excited to share that Gold Standard’s pipeline is full of new, innovative solutions that will be added to our platform”.
The AIX1000 systems installed base and market share continues to grow amid increasing rates of syphilis in the United States. According to the Centers for Disease Control and Prevention the rate of syphilis cases in the U.S. increased 74% from 2012-20161.
1. 2016 Sexually transmitted diseases surveillancehttps://www.cdc.gov/std/stats16/Syphilis.htm (Accessed 02/23/18).
ABOUT GOLD STANDARD DIAGNOSTICS, CORP.
Gold Standard Diagnostics, Corp. is a privately held clinical diagnostics company based in Davis, California. The company develops, manufactures and distributes a portfolio of instrumentation and diagnostic test kits to clinical laboratories in the U.S., EMEA, Asia, and South America. In addition to the AIX1000, current product offerings include the Thunderbolt™ and Bolt®, open format instrumentation platforms for enzyme and chemiluminescence immunoassays, and an extensive menu of serology tests across autoimmune, infectious, and endocrine diseases.